Directorio

We are doing this study to find out if an experimental drug called PT217 (the study drug) is a safe and effective option for people who have neuroendocrine carcinomas. We want to see how this drug works when it is given on its own and in combination with standard chemotherapy and/or immunotherapy drugs.

We are doing this study to find out if a new type of assessment works well for middle-aged and older adults with sickle cell disease (SCD). We want to see if this assessment is useful in detecting changes in health. We hope the assessment can provide useful information to help improve the quality of life for adults with sickle cell disease.

We are doing this study to find out if an experimental drug called lasofoxifene (the study drug) is a safe and effective option for breast cancer. We want to see if the study drug combined with another drug called abemaciclib has better results than treatment with abemaciclib plus fulvestrant.

We are doing this study to learn more about how different factors in pregnancy lead to healthy babies. Specifically, whether factors related to father's health affect the placenta and baby, what part of placental and fetal genes are related to placenta health and baby growth, and to find out the best time to deliver when the mother has gestational diabetes.

If you can join, you will be placed in Part A or Part B based on when you start. In Part A, you will get one of three study medicines: SPY001, SPY002, or SPY003. In Part B, you will get one of these medicines, a mix of two medicines, or a placebo, which does nothing. The study will last about 97 weeks, and you will have around 20 visits or phone calls. During these, doctors will do tests like blood draws, endoscopy with biopsy, heart checks, and x-rays.

We are doing this study to find out if the Nectero EAST System® (the study procedure) is a safe and effective option for treating abdominal aortic aneurysms that are small to medium in size.

If you participate, you will be asked to provide a blood draw of about 5.4 mL, or 1/3 tablespoon, of blood. If you are one of the first 20 subjects, you may have the chance to participate in one additional blood draw.

We are doing this study to find out if an experimental drug called Zorevunersen (the study drug) can effectively reduce the frequency of major motor seizures for children who have Dravet syndrome.